We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

22 hedge funds and large institutions have $47.9M invested in BioXcel Therapeutics in 2018 Q1 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1.88% more ownership

Funds ownership: 0% → 1.88% (+1.9%)

Holders
22
Holders Change
+22
Holders Change %
–
% of All Funds
0.5%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$17.4M
2
AIM
Artemis Investment Management
United Kingdom
+$12.6M
3
Barclays
Barclays
United Kingdom
+$6.45M
4
California Public Employees Retirement System
California Public Employees Retirement System
California
+$3.43M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.08M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$17.1M +$17.4M +104,167 New
AIM
2
Artemis Investment Management
United Kingdom
$12.2M +$12.6M +75,652 New
Barclays
3
Barclays
United Kingdom
$6.33M +$6.45M +38,641 New
California Public Employees Retirement System
4
California Public Employees Retirement System
California
$3.36M +$3.43M +20,519 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.02M +$3.08M +18,438 New
AC
6
Ascend Capital
California
$2.05M +$2.09M +12,531 New
MIM
7
Monashee Investment Management
Massachusetts
$922K +$939K +5,625 New
MWNA
8
Marshall Wace North America
New York
$670K +$682K +4,088 New
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$609K +$620K +3,716 New
DIM
10
DC Investments Management
Virginia
$364K +$371K +2,222 New
Millennium Management
11
Millennium Management
New York
$316K +$322K +1,931 New
PAM
12
Prudence Asset Management
Hong Kong
$307K +$313K +1,875 New
Goldman Sachs
13
Goldman Sachs
New York
$285K +$291K +1,743 New
Wellington Management Group
14
Wellington Management Group
Massachusetts
$116K +$118K +708 New
LCM
15
Laurion Capital Management
New York
$102K +$104K +625 New
PHK
16
Point72 Hong Kong
Hong Kong
$63K +$64.6K +387 New
Morgan Stanley
17
Morgan Stanley
New York
$30K +$30.6K +183 New
UBS Group
18
UBS Group
Switzerland
$27K +$27.7K +166 New
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
$25K +$25K +150 New
Bank of America
20
Bank of America
North Carolina
$9K +$8.85K +53 New
CCA
21
Catalyst Capital Advisors
New York
$5K +$4.67K +28 New
TRCT
22
Tower Research Capital (TRC)
New York
$1K +$1K +6 New

BTAI Hedge Fund Activity: Q1 2018 in Review

22 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2018, worth a combined $47.9M.

Buyers outnumbered sellers: 22 funds opened new BTAI positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $17.4M.

  • 22 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2018, up from 0 in Q4 2017.
  • Funds reported $47.9M of BioXcel Therapeutics stock for Q1 2018.
  • 22 funds opened new BioXcel Therapeutics positions in Q1 2018 and 0 closed out, a net change of +22 holders.
  • The largest BioXcel Therapeutics buyer in Q1 2018 was Fidelity Investments, an estimated $17.4M added.

Based on aggregated 13F filings for Q1 2018.